primary human peripheral blood-derived cd4 t cells stem cell Search Results


primary human peripheral blood-derived cd4+ t cells stem cell  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc primary human peripheral blood-derived cd4+ t cells stem cell
In vitro treatment of activated <t>CD4+</t> T cells with Y201 and Y202 EVs (n=2, mean events >18,000 counted) A) Proliferative cycles. B) Proliferative index C) Polarisation of activated T cells in the absence and presence of Y201 EVs and Y202 EVs (n=2, mean events >32,000 counted). D/E) Total peritoneal exudate cell (PEC) counts following zymosan (D) or schistosome egg (E) induced inflammation in the absence and presence of Y201 EVs and Y202 EVs. F/G) Examination of TCR+CD4+, naïve and central memory T cells in zymosan or schistosome egg induced inflammation in the absence and presence of Y201 EVs and Y202 EVs (n=3). One-Way ANOVA with Bonferroni post hoc testing,*p<0.05, **p<0.01, ***p<0.001.
Primary Human Peripheral Blood Derived Cd4+ T Cells Stem Cell, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+human+peripheral+blood-derived+cd4++t+cells+stem+cell/primary+human+peripheral+blood+derived+cd4++t+cells+stem+cell/bio_rxiv__2024__09__05__609844-177-22-25
Average 90 stars, based on 1 article reviews
primary human peripheral blood-derived cd4+ t cells stem cell - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


In vitro treatment of activated CD4+ T cells with Y201 and Y202 EVs (n=2, mean events >18,000 counted) A) Proliferative cycles. B) Proliferative index C) Polarisation of activated T cells in the absence and presence of Y201 EVs and Y202 EVs (n=2, mean events >32,000 counted). D/E) Total peritoneal exudate cell (PEC) counts following zymosan (D) or schistosome egg (E) induced inflammation in the absence and presence of Y201 EVs and Y202 EVs. F/G) Examination of TCR+CD4+, naïve and central memory T cells in zymosan or schistosome egg induced inflammation in the absence and presence of Y201 EVs and Y202 EVs (n=3). One-Way ANOVA with Bonferroni post hoc testing,*p<0.05, **p<0.01, ***p<0.001.

Journal: bioRxiv

Article Title: Extracellular vesicle bioactivity and potential clinical utility is determined by mesenchymal stromal cell clonal subtype

doi: 10.1101/2024.09.05.609844

Figure Lengend Snippet: In vitro treatment of activated CD4+ T cells with Y201 and Y202 EVs (n=2, mean events >18,000 counted) A) Proliferative cycles. B) Proliferative index C) Polarisation of activated T cells in the absence and presence of Y201 EVs and Y202 EVs (n=2, mean events >32,000 counted). D/E) Total peritoneal exudate cell (PEC) counts following zymosan (D) or schistosome egg (E) induced inflammation in the absence and presence of Y201 EVs and Y202 EVs. F/G) Examination of TCR+CD4+, naïve and central memory T cells in zymosan or schistosome egg induced inflammation in the absence and presence of Y201 EVs and Y202 EVs (n=3). One-Way ANOVA with Bonferroni post hoc testing,*p<0.05, **p<0.01, ***p<0.001.

Article Snippet: To determine MSC-derived EV immunomodulation for deactivation and suppression of T cell proliferation, suspension cultures of 1.0×10 5 primary human peripheral blood-derived CD4+ T cells (Stem Cell Technologies) were grown in RPMI-1640 with 10% FBS 1% P/S (Gibco, Cat: 10363083) and were pre-treated for 6hrs with 20X EVs isolated from serum-free conditioned medium collected over 24hrs culture from 2.0×10 6 of Y201 or Y202 MSCs.

Techniques: In Vitro